Deficient expression of the DPD gene is caused by epigenetic modification in biliary tract cancer cells, and induces high sensitivity to 5-FU treatment

International Journal of Oncology

Volumn 29, Issue 2, 2006, Pages 429-435

  Sato, Ken ^a   Kitajima, Yoshihiko ^a   Miyoshi, Atsushi ^a   Koga, Yasuo ^a   Miyazaki, Kohji ^a  

^a SAGA UNIVERSITY   (Japan)

Author keywords

5 FU; Biliary tract cancer; DPD; Methylation

Indexed keywords

ANTINEOPLASTIC ANTIMETABOLITE; ENZYME INHIBITOR; FLUOROURACIL; HISTONE DEACETYLASE; HYDROXAMIC ACID; PROTEIN SYNTHESIS INHIBITOR; TETRAZOLIUM; THIAZOLE DERIVATIVE; THIAZOLYL BLUE; TRICHOSTATIN A;

ARTICLE; BILIARY TRACT TUMOR; DRUG ANTAGONISM; GENE EXPRESSION REGULATION; GENETIC EPIGENESIS; HUMAN; METABOLISM; MOLECULAR GENETICS; NUCLEOTIDE SEQUENCE; TUMOR CELL LINE;

ANTIMETABOLITES, ANTINEOPLASTIC; BASE SEQUENCE; BILIARY TRACT NEOPLASMS; CELL LINE, TUMOR; ENZYME INHIBITORS; EPIGENESIS, GENETIC; FLUOROURACIL; GENE EXPRESSION REGULATION, NEOPLASTIC; HISTONE DEACETYLASES; HUMANS; HYDROXAMIC ACIDS; MOLECULAR SEQUENCE DATA; PROTEIN SYNTHESIS INHIBITORS; TETRAZOLIUM SALTS; THIAZOLES;

EID: 33846538518     PISSN: 10196439     EISSN: 17912423     Source Type: Journal    
DOI: 10.3892/ijo.29.2.429     Document Type: Article

References (39)

1. Okada S, Ishii H, Nose H, et al: A phase II study of cisplatin in patients with biliary tract carcinoma. Oncology 51: 51515-51517, 1994. (Pubitemid 24347034)
2. Raderer M, Hejna MH, Valencak JB, et al: Two consecutive phase II studies of 5-fluorouracil/leucovorin/mitomycin C and of gemcitabine in patients with advanced biliary cancer. Oncology 56: 177-180, 1999. (Pubitemid 29161284)
3. Sanz-Altamira PM, O'Reilly E, Stuart KE, Raeburn L, Steger C, Kemeny NE and Saltz LB: A phase II trial of irinotecan (CPT-11) for unresectable biliary tree carcinoma. Ann Oncol 12: 501-504, 2001. (Pubitemid 32472105)
4. Todoroki T: Chemotherapy for gallbladder carcinoma - A surgeon's perspective. Hepatogastroenterology 47: 948-955 2000.
5. Ellis PA, Norman A, Hill A, O'Brien ME, Nicolson M, Hickish T and Cunningham D: Epirubicin, cisplatin and infusional 5-fluorouracil (5-FU) (ECF) in hepatobiliary tumours. Eur J Cancer 31: 1594-1598, 1995.
6. Sanz-Altamira PM, Ferrante K, Jenkins RL, Lewis WD, Huberman MS and Stuart KE: A phase II trial of 5-fluorouracil, leucovorin, and carboplatin in patients with unresectable biliary tree carcinoma. Cancer 82: 2321-2325, 1998. (Pubitemid 28283437)
7. Gebbia V, Giuliani F, Maiello E, et al: Treatment of inoperable and/or metastatic biliary tree carcinomas with single-agent gemcitabine or in combination with levofolinic acid and infusional fluorouracil: results of a multicenter phase II study. J Clin Oncol 19: 4089-4091, 2001. (Pubitemid 32976699)
8. Heggie GC, Sommadossi JP, Cross DS, Huster WJ and Diasio RB: Clinical pharmacokinetics of 5-fluorouracil and its metabolites in plasma, urine, and bile. Cancer Res 47: 2203-2206, 1987. (Pubitemid 17074634)
9. Diassio RB: The role of dihydropyrimidine dehydrogenase (DPD) modulation in 5-FU pharmacology. Oncology 12 (Suppl. 7): 23-27, 1998.
10. Beck A, Etienne MC, Cheradame S, Fischel JL, Formento P, Renee N and Milano G: A role for dihydropyrimidine dehydrogenase and thymidylate synthase in tumour sensitivity to fluorouracil. Eur J Cancer 30A: 1517-1522, 1994. (Pubitemid 24343014)
11. Fischel JL, Etienne MC, Spector T, Formento P, Renee N and Milano G: Dihydropyrimidine dehydrogenase: a tumoral target for fluorouracil modulation. Clin Cancer Res 1: 991-996, 1995.
12. Nita ME, Tominaga O, Nagawa H, Tsuruo T and Muto M: Dihydropyrimidine dehydrogenase but not thymidylate synthase expression is associated with resistance to 5-fluorouracil in colorectal cancer. Hepatogastroenterology 45: 2117-2122, 1998. (Pubitemid 29055788)
13. Kirihara Y, Yamamoto W, Toge T and Nishiyama M: Dihydropyrimidine dehydrogenase, multidrug resistansce associated protein, and thymidylate synthase gene expression levels can predict 5-fluorouracil resistance in human gastrointestinal cancer cells. Int J Oncol 14: 551-556, 1999.
14. Ishikawa Y, Kubota T, Otani Y, et al: Dihydropyrimidine dehydrogenase activity and messenger RNA level may be related to antitumor effect of 5-fluorouracil on human tumor xenografts in nude mice. Clin Cancer Res 5: 883-889, 1999. (Pubitemid 29180841)
15. Etienne MC, Cheradame S, Fischel JL, et al: Response to fluorouracil therapy in cancer patients: the role of tumoral dihydropyrimidine dehydrogenase activity. J Clin Oncol 13: 1663-1670, 1995.
16. Jiang W, Lu Z, He Y and Diasio RB: Dihydropyrimidine dehydrogenase activity in hepatocellular carcinoma: implication in 5-fluorouracil-based chemotherapy. Clin Cancer Res 3: 395-399, 1997. (Pubitemid 27158063)
17. McLeod HL, Sludden J, Murray GI, et al: Characterization of dihydropyrimidine dehydrogenase in human colorectal tumours. Br J Cancer 77: 461-465, 1988.
18. Collie-Dugaid ESR, Johnston SJ, Powrie RH, et al: Cloning and initial characterization of the human DPYD gene promoter. Biochem Biophys Res Commun 271: 28-35, 2000.
19. Van Kuilenburg ABP, Haasies J, Richel DJ, et al: Clinical implication of dihydropyrimidine dehydrogenase (DPD) deficiency in patients with severe 5-Fluorouracil-assaociated toxicity: Identification of new mutations in the DPD gene. Clin Cancer Res 6: 4705-4712, 2000.
20. Raida M, Schwabe W, Hausler P, van Kuilenburg ABP, van Gennip AH, Benke D and Hoffken K: Prevalence of a common point mutation in the dihydropyrimidine dehydrogenase (DPD) gene within the 5′-splice donor site of Intron 14 in patients with severe 5-fluorouracil (5-FU)-related toxicity compared with controls. Clin Cancer Res 7: 2832-2839, 2001.
21. Collie-Dugaid ESR, Etienne MC, Milano G and McLeod HL: Known variant DPYD alleles do not explain DPD deficiency in cancer patients. Pharmacogenetics 10: 217-223, 2000.
22. Uetake H, Ichikawa W, Takechi T, Fukushima M, Nihei Z and Sugihara K: Relationship between intratumoral dihydropyrimidine dehydrogenase activity and gene expression in human colorectal cancer. Clin Cancer Res 5: 2836-2839, 1999.
23. Johnston SJ, Ridge SA, Cassidy J and McLeod HL: Regulation of dihydropyrimidine dehydrogenase in colorectal cancer. Clin Cancer Res 5: 2566-2570, 1999.
24. Sato K, Kitajima Y, Kohya N, et al: Deficient MGMT and proficient hMLH1 expression renders gallbladder carcinoma cells sensitive to alkylating agents through G2-M cellcycle arrest. Int J Oncol 26: 1653-1661, 2005.
25. Jiao W, Kitajima Y, Ogawa A and Miyazaki K: Establishment and characterization of human hilar bile duct carcinoma cell line and cell strain. J Hepatobiliary Pancreat Surg 7: 417-425, 2000.
26. Paulin R, Grigg GW, Davey MW and Piper AA: Urea improves efficiency of bisulfite-mediated sequencing of 5′-methylcytosine in genomic DNA. Nucleric Acids Res 26: 5009-5010, 1998.
27. Kelsen D: Neoadjuvant therapy for upper gastrointestinal tract cancers. Curr Opin Oncol 8: 321-328, 1994.
28. Wils J: Treatment of gastric cancer. Curr Opin Oncol 10: 357-361, 1998.
29. Shestopal SA, Johnson MR and Diasio RB: Molecular cloning and characterization of the human dihydropyrimidine dehydrogenase promoter. Biochem Biophys Acta 1494: 162-169, 2000.
30. Noguchi T, Tanimoto K, Shimokuni T, et al: Aberrant Methylation of DPYD promoter, DPYD expression, and cellular sensitivity to 5-fluorouracil in cancer cells. Clin Cancer Res 10: 7100-7107, 2004.
31. Smith SC and Karran P: Epigenetic silencing of the DNA repair enzyme O6-methylguanine-DNA methyltransferase in Mex-human cells. Cancer Res 52: 5257-5263, 1992.
32. Toyota M, Sasaki Y, Satoh A, et al: Epigenetic inactivation of CHFR in human tumors. Proc Natl Acad Sci USA 100: 7818-7823, 2003.
33. Fleisher AS, Esteller M, Wang S, et al: Hypermethylation of the hMLH1 gene promoter in human gastric cancers with microsatellite instability. Cancer Res 59: 1090-1095, 1999.
34. Ng HH and Bird A: DNA methylation and chromatin modification. Curr Opin Genet Dev 9: 158-163, 1999.
35. Baylin SB, Esteller M, Rountree MR, Bachman KE, Schuebel K and Herman JG: Agerrant patterns of the DNA methylation, chromatin formation and gene expression in cancer. Human Mol Genet 10: 687-692, 2001.
36. Nervi C, Borello U, Fazi F, Buffa V, Pelicci PG and Cossu G: Inhibition of histone deacetylase activity by trichostatin A modulates gene expression during mouse embryogenesis without apparent toxicity. Cancer Res 61: 1247-1249, 2001.
37. Dobosy JR and Selker EU: Emerging connections between DNA methylation and histone acetylation. Cell Mol Life Sci 58: 721-727, 2001.
38. Soejima H, Joh K and Mukai T: Gene silencing in DNA damage repair. Cell Mol Life Sci 61: 2168-2172, 2004.
39. Bachman KE, Park BH, Rhee I, et al: Histone modifications and silencing prior to DNA methylation of a tumor suppressor gene. Cancer Cell 3: 89-95, 2003.